Choong-wae, Fujirebio sign agreement over Lumipulse G1200

Published: 2010-08-13 06:57:00

Updated: 2010-08-13 06:57:00

Choongwae-Pharm announced on August 11 that it has signed an exclusive distribution agreement with Fujirebio Diagnostics, Inc. of Japan to distribute the latter’s diagnostic agent “Lumipulse G1200.”

Lumipulse G1200 is a biomarker for cancer and other 40 diseases, which can be detected within ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK